radretumab radretumab radretumab is an antineoplastic. philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of iodine-131 to an antibody which binds to fibronectin extra domain-b for treatment of hodgkin lymphoma. radretumabmonoclonal antibodytypewhole antibodysourcehumantargetfibronectinclinical dataatc codenoneidentifierscas number1253180-81-2 nchemspidernoneunii6jva140ub4 ny (what is this?) (verify)